Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05978752
Other study ID # 2023-0437
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date December 2023
Est. completion date November 2025

Study information

Verified date July 2023
Source Second Affiliated Hospital, School of Medicine, Zhejiang University
Contact Hongxia Li, Doctor
Phone +8618252006898
Email lhx100918@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The patients with GOV1 esophagogastric varices will be treated with gastric variceal tissue gel injection, at the same time, the esophageal varices were treated with ligation, sclerotherapy, or no treatment. A new method for the treatment of esophageal varices will be proposed to improve the effective rate and reduce the recurrence rates and mortality, shorter hospital stays, and lower treatment costs, while further expanding HVPG testing to develop the best strategy for secondary prevention of endoscopic treatment in patients with GOV1 type esophageal and gastric varices.


Description:

Cirrhotic portal hypertension can cause esophageal and gastric varices, and esophageal and gastric varices bleeding (EGVB) were associated with portal vein pressure. At present, the gold standard for detecting portal pressure in clinical practice is hepatic venous pressure gradient (HVPG). For Sarin classification GOV1 of esophagogastric varices are from a single origin, the left gastric vein. If the fundus varicose veins receive complete embolization treatment, the esophageal variceal blood flow should be completely blocked, and such patients do not need to perform esophageal surgery. However, this has not been reported in the literature. Patients with esophageal and gastric varices identified by CT as GOV1 will be enrolled, all of whom will receive HVPG detects. The patients were randomly divided into three groups. The patients in group A will receive endoscopic gel embolization for gastric varices and esophageal varices ligation treatment, group B patients will receive endoscopic gastric variceal tissue glue embolization and esophageal variceal sclerotherapy treatment, the patients in group C will receive endoscopic gelatinization of gastric fundus varices (esophageal varices were not treated). Patients in the three groups were followed up with CTP and gastroscopy 1 month, 3 months, and 6 months after the initial treatment, and additional endoscopic treatment will be provided if necessary. If bleeding occurs again during this period, timely treatment (medication, endoscopy, intervention or surgery) is required according to the condition. A new method for the treatment of esophageal varices will be proposed to improve the effective rate and reduce the recurrence rates and mortality, shorter hospital stays, and lower treatment costs, while further expanding HVPG testing to develop the best strategy for secondary prevention of endoscopic treatment in patients with GOV1 type esophageal and gastric varices.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 57
Est. completion date November 2025
Est. primary completion date June 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - GOV1 esophageal and gastric varices identified by CT; more than 18 years old; Exclusion Criteria: - Complicated with liver cancer, severe cardiopulmonary insufficiency, stage III and above hepatic encephalopathy, severe natural portal shunt formation, and previous treatment of portal hypertensive bleeding (including endoscopic, interventional, and surgical procedures).

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Endoscopic gel embolization of gastric fundus varices and ligation of esophageal varices
For patients with GOV1 esophagogastric varices, gastric varices will be treated with endoscopic gelatinous embolization, esophageal varices will be treated with ligation.
Endoscopic gel embolization of gastric fundus varices and sclerotherapy of esophageal varices
For patients with GOV1 esophagogastric varices, gastric varices will be treated with endoscopic gelatinous embolization, esophageal varices will be treated with sclerotherapy.
Endoscopic gelatinous embolization of gastric varices (esophageal varices not treated)
For patients with GOV1 esophagogastric varices, only gastric varices will be treated with endoscopic gelatinous embolization, esophageal varices will not be treated.

Locations

Country Name City State
n/a

Sponsors (5)

Lead Sponsor Collaborator
Second Affiliated Hospital, School of Medicine, Zhejiang University Jinhua Hospital Affiliated to Zhejiang University, Lanxi People's Hospital, Lishui Country People's Hospital, Shandong Provincial Hospital Affiliated to Shandong First Medical University

Outcome

Type Measure Description Time frame Safety issue
Primary hemostasis rate the percentage of hemostasis 6 month
Secondary Postoperative bleeding recurrence rate Rebleeding rate after endoscopic treatment: including hematemesis and/or black stool, hemoglobin decrease >10g/L 6 month
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT05055713 - A Randomized Controlled Study on the Treatment of Cirrhosis Combined With Hypersplenism N/A
Recruiting NCT02945930 - Study the Safety and Efficacy of "Compont Medical Glue" in the Treatment of Esophagogastric Varices N/A
Completed NCT04823780 - The Effects of Early Enteral Nutrition on Endoscopic Therapy of Esophagogastric Varices in Liver Cirrhosis
Completed NCT03244332 - HEMOCC Study. Hemostasis in Cirrhotic Children. N/A
Completed NCT02991612 - Rifaximin in Patients With Gastroesophageal Variceal Bleeding N/A
Recruiting NCT02964195 - Efficacy of Rifaximin in Treatment of Cirrhotic Gastroesophageal Variceal Bleeding N/A
Completed NCT00004641 - A Study to Prevent Complications of High Blood Pressure Caused by Hepatitis in Patients With Cirrhosis Phase 2
Completed NCT02593799 - Non-invasive Prediction of Esophageal Varices in Liver Cirrhosis: A Multicenter Observational Study
Recruiting NCT02719119 - Trial of Monthly Versus Bi-weekly Endoscopic Variceal Ligation for the Prevention of Esophageal Variceal Rebleeding N/A
Recruiting NCT02385422 - The Effect of Carvedilol Vs Propranolol in Cirrhotic Patients With Variceal Bleeding Phase 4
Completed NCT00838864 - Comparison of 3 Days and 7 Days Intravenous Ceftriaxone Prophylaxis for Variceal Bleeding Phase 4
Not yet recruiting NCT03130127 - Continuous Versus Bolus Infusion of Terlipressin for Portal Hypertension Related Bleeding in Liver Cirrhosis N/A
Active, not recruiting NCT05979935 - Prediction of Esophageal Varices in Liver Cirrhosis Using Tongue Bioinformatics
Recruiting NCT02504723 - Carvedilol as an Adjunct to Endoscopic Cyanoacrylate Injection for Secondary Prophylaxis of Gastric Variceal Bleeding Phase 4
Withdrawn NCT00475592 - Validation of Esophageal Variceal Grading: A Comparative Study of Upper Gastrointestinal (GI) Endoscopy and Capsule Endoscopy N/A
Completed NCT05331768 - Comparison of Endoscopic Band Ligation Plus 24-hour Versus 72-hour Terlipressin Therapy N/A
Completed NCT04210297 - Development and Validation of an Noninvasive Model for Predicting High Risk Esophageal Varices in Cirrhosis
Recruiting NCT02311608 - Effects of Terlipressin When Usual Somatostatin or Octreotide Dose Fails N/A
Completed NCT04976543 - Safety of Anticoagulant Therapy After Endoscopic Treatment Phase 4
Recruiting NCT02695732 - The Effect of Carvedilol VS Endoscopic Therapy in Primary Prophylaxis of High-risk Esophageal Gastric Variceal Bleeding Phase 4